The increase in AIF and caspase 3 expression in prostate cancer cells treated with 10 μg/mL of [99Tc]Sestamibi confirmed that this radiopharmaceutical can trigger the apoptosis. This evidence concerns the gene CASP3 and prostate carcinoma.